Clinical trials
IDH Mutation clinical trials
Below are recruiting idh mutation clinical trials, each written for real people, not researchers. We’re tracking 12 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07301268RecruitingPhase 2
GI-102 with or without pembrolizumab before brain surgery
This trial is testing a new drug called GI-102, given alone or with pembrolizumab, before surgery for a type of brain tumor called glioblastoma or grade 4 astrocytoma. The goal is to see if these drugs can help shrink the tumor before it's removed.
Rochester, MinnesotaAges 18 years+ - NCT05345002RecruitingPhase 2
ATRA plus PD-1 therapy for IDH-mutant recurrent brain tumors
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05190172Recruiting
Proton versus photon radiation for IDH-mutated brain tumors
This trial compares two types of radiation—proton therapy versus photon (standard) therapy—for adults with an IDH-mutated grade 2 or 3 brain tumor. The goal is to see which approach works better and/or causes fewer side effects while treating the tumor.
OsloAges 18–65 - NCT07755397RecruitingPhase 1
Study of JBI-778 for lung, brain, and salivary gland tumors
This trial tests a new oral medication, JBI-778, in patients with certain types of lung cancer, brain tumors, or salivary gland cancer. The drug is designed to target specific genetic changes in these tumors, and the study aims to assess its safety and effectiveness.
Surat, GujaratAges 18 years+ - NCT05401097RecruitingPhase 2
Venetoclax plus IDH-targeted pills for AML patients who can’t get intensive chemo
This Phase 2 trial tests different ways of using medicines that target IDH mutations (IDH-targeted treatment) plus venetoclax in people newly diagnosed with IDH-mutated AML. It’s designed for patients who cannot safely receive intensive induction chemotherapy, to see which approach works best and is tolerable.
Aurora, ColoradoAges 18 years+ - NCT07260175RecruitingPhase 2
Ivosidenib maintenance for IDH1-mutated bile duct cancer
This trial tests a targeted pill called ivosidenib for people with a specific type of bile duct cancer (IDH1-mutated) who have completed surgery and chemotherapy. The goal is to see if taking ivosidenib as a maintenance therapy helps keep the cancer from coming back.
AachenAges 18 years+ - NCT04233788Recruiting
Brain mass imaging study using MRI to learn what causes it
This study uses MRI scanning to better describe a suspected brain mass and understand what it might be. You may be asked to lie in the scanner for about one hour, if you meet the study’s safety and eligibility rules.
BernAges 18 years+ - NCT06180434Recruiting
Short-term outcomes of proton vs photon radiation for IDH-mutated gliomas
This study looks at the short-term results of proton and photon radiation therapy in people with IDH-mutated grade 2 or 3 gliomas. It compares the two types of radiation to see how well they work and what side effects might occur.
RotterdamAges 18 years+ - NCT06636162RecruitingEarly Phase 1
Testing DSP-0390 before surgery for gliomas
This trial tests a drug called DSP-0390 in people with gliomas (a type of brain tumor). You take the drug for a short time before your scheduled surgery to see how it affects the tumor. It might help doctors find new ways to treat these tumors.
St Louis, MissouriAges 18 years+ - NCT07547163Recruiting
Patient feedback on low-grade brain tumor treatment
This study asks patients with a specific type of low-grade brain tumor (IDH mutant grade 2 glioma) to share their experiences and quality of life while receiving a treatment called vorasidenib, with or without radiation. Your feedback helps doctors understand how well the treatment works from your perspective.
MilanAges 18 years+ - NCT07405372Recruiting
IDH mutation PET/MRI scan for brain tumors
This study uses a special type of PET/MRI scan to look for a common genetic change (IDH mutation) in brain tumors (gliomas). The goal is to improve how doctors diagnose and treat these tumors.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT07089641RecruitingPhase 1
Testing a new pill for EGFR-mutated glioblastoma
This trial tests a new pill called ERAS-801 for people with a type of brain tumor (glioblastoma) that has a specific change in the EGFR gene. The study is for patients whose tumor has come back after treatment, or for those 70 or older who are newly diagnosed.
Los Angeles, CaliforniaAges 18 years+
Hear when a new IDH Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for idh mutation?
- Yes. Clin2 currently lists 12 recruiting idh mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a idh mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a idh mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.